Free tool
FAERS Monitor: Dyanavel Xr 20
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210526 or its brand name (Dyanavel Xr 20, Amphetamine, Amphetamine Aspartate/Dextroamphetamine Sulfate). Reports on generic versions are filed under their own applications.
Reports
6,459
Serious
5,279
82% of reports
Hospitalization
1,474
Death reported
3,009
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxicity to various agents1,624
- drug abuse1,305
- completed suicide666
- overdose414
- death355
- cardiac arrest282
- cardio-respiratory arrest266
- drug ineffective266
- off label use218
- respiratory arrest216
- fatigue191
- drug dependence188
- drug interaction187
- substance abuse162
- nausea160
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 12 |
| 2006 | 13 |
| 2007 | 15 |
| 2008 | 16 |
| 2009 | 1 |
| 2010 | 7 |
| 2011 | 42 |
| 2012 | 36 |
| 2013 | 227 |
| 2014 | 264 |
| 2015 | 394 |
| 2016 | 232 |
| 2017 | 299 |
| 2018 | 464 |
| 2019 | 524 |
| 2020 | 498 |
| 2021 | 437 |
| 2022 | 481 |
| 2023 | 539 |
| 2024 | 709 |
| 2025 | 784 |
| 2026 | 448 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,700 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| substance abuseSignal | 162 | 66.1 | 56.7 | 10,121 |
| drug abuseSignal | 1,305 | 51.8 | 49.4 | 64,261 |
| toxicity to various agentsSignal | 1,624 | 31.7 | 30.3 | 48,101 |
| completed suicideSignal | 666 | 26.2 | 24.4 | 16,070 |
| respiratory arrestSignal | 216 | 25.7 | 22.6 | 5,075 |
| cardio-respiratory arrestSignal | 266 | 20.8 | 18.5 | 4,983 |
| cardiac arrestSignal | 282 | 11.2 | 10.0 | 2,599 |
| overdoseSignal | 414 | 6.3 | 5.7 | 1,840 |
| drug interactionSignal | 187 | 3.8 | 3.3 | 393 |
| drug dependenceSignal | 188 | 3.8 | 3.3 | 389 |
| death | 355 | 1.3 | 1.2 | 32 |
| off label use | 218 | 0.8 | 0.7 | 10 |
| fatigue | 191 | 0.8 | 0.7 | 10 |
| nausea | 160 | 0.7 | 0.6 | 29 |
| drug ineffective | 266 | 0.7 | 0.6 | 50 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.